Glenmark Pharmaceuticals shares fall 2.34% after Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)
Why did Glenmark Pharmaceuticals Ltd shares fall today?
As of Tuesday at 09:04 AM, shares of Glenmark Pharmaceuticals Ltd are trading at ₹2,281.6, representing a decline of 2.34% from the previous close. The stock weakness comes despite the company announcing the launch of a new product through its US subsidiary, Glenmark Therapeutics Inc. Investors appear to be reacting cautiously to the announcement, possibly weighing the revenue potential against broader market sentiment or expectations.
Glenmark Therapeutics Inc., USA has launched Pump Packs for Adapalene Gel USP, 0.1% (OTC) in the United States market. This product is comparable to the active ingredient found in Differin® Gel, 0.1%, a well-known over-the-counter acne treatment. According to Nielsen® syndicated data for the 52-week period ending September 5, 2026, the Differin® Gel 0.1% (OTC) market generated annual sales of approximately $45.8 million, indicating a substantial market opportunity for Glenmark's offering. The company has filed the announcement with both the National Stock Exchange of India (NSE) and BSE Limited as required under listing norms.
While the launch is a positive business development, the market reaction suggests that investors may not yet be fully pricing in the revenue contribution from this product, or there may be other factors at play that are dragging the stock lower today. The $45.8 million addressable market is meaningful but represents a fraction of Glenmark's overall revenue base, and the stock may be adjusting from earlier highs or responding to broader sector dynamics in the pharmaceutical space.
What does Glenmark Pharmaceuticals Ltd do?
Glenmark Pharmaceuticals Limited is a publicly traded company listed on the National Stock Exchange of India Limited and BSE Limited, trading under the scrip name GLENMARK with the scrip code 532296 and ISIN INE935A01035. Its operations in the pharmaceutical sector are carried out in part through Glenmark Therapeutics Inc., USA, a subsidiary that develops and markets drug products for the United States market. The company is led at the compliance level by Rashmi Khandelwal, who serves as Company Secretary and Compliance Officer, and it maintains corporate relationship and regulatory filings with both stock exchanges from its Mumbai offices.
Glenmark Therapeutics Inc., USA recently announced the launch of Adapalene Gel USP, 0.1% (OTC) in new pump packs, an over-the-counter dermatology product whose active ingredient can be compared to that of Differin® Gel, 0.1%. The over-the-counter market for this type of gel is a significant commercial opportunity: according to Nielsen® syndicated data for the 52-week period ending September 5, 2026, the Differin® Gel, 0.1% (OTC) market achieved annual sales of approximately $45.8 million. By bringing its Adapalene Gel USP, 0.1% to market in pump-pack form, Glenmark positions itself within this well-established therapeutic category, complementing the company's broader portfolio of pharmaceutical offerings.
Glenmark Pharmaceuticals Ltd Financials
In CroresGlenmark Pharmaceuticals reported revenue of ₹3,760.28 crores in the March 2026 quarter, which rose to ₹3,931.73 crores in the June 2026 quarter, reflecting a quarter-over-quarter increase of approximately 4.6%. Net profit followed a strong upward trend, climbing from ₹301.41 crores in March 2026 to ₹482.92 crores in June 2026, a significant rise of about 60.2%. While revenue showed steady quarter-over-quarter growth, the jump in net profit was notably sharper, suggesting improved profitability during the period, potentially driven by better margins, operational efficiencies, or favourable business conditions. Overall, both revenue and profit displayed clear growth momentum between the two quarters, with profitability expanding at a much faster pace than top-line revenue.
Glenmark Pharmaceuticals Ltd Shareholding Pattern
Promoter holding stands at 46.65% of the total share capital. Foreign Institutional Investors (FIIs) hold 20.89% stake in the company, while Domestic Institutional Investors (DIIs) hold 18.6%. Public shareholders hold the remaining 13.85% stake in Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd FAQs
Q: Why did Glenmark shares fall 2.34% today?
Glenmark Therapeutics Inc. USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC). This corporate action caught investor attention, leading to increased trading activity in the stock.
Q: What is the shareholding pattern of Glenmark Pharmaceuticals Ltd?
As per the latest data, promoters hold 46.65% stake in Glenmark Pharmaceuticals Ltd, while FII holding stands at 20.89%. Domestic institutional investors hold 18.6%, and public shareholders account for 13.85% of the equity.
Q: What is the current stock price of Glenmark Pharmaceuticals Ltd?
Glenmark Pharmaceuticals Ltd shares are currently trading at ₹2281.6, recording a decline of 2.34% from the previous close.
Q: What is the market capitalization of Glenmark Pharmaceuticals Ltd?
The company currently has a market capitalization of ₹64392.38 crore, reflecting its valuation in the Indian equity market.